Simulations Plus (NASDAQ:SLP) Shares Cross Above 200 Day Moving Average – What’s Next?

Simulations Plus, Inc. (NASDAQ:SLP)’s stock price crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $16.21 and traded as high as $18.42. Simulations Plus shares last traded at $18.42, with a volume of 104,375 shares traded.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SLP. Weiss Ratings upgraded shares of Simulations Plus from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, July 10th. Craig Hallum downgraded Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 price target on the stock. in a research report on Thursday, June 18th. William Blair lowered Simulations Plus from an “outperform” rating to a “market perform” rating in a research note on Wednesday, June 17th. Finally, Wall Street Zen cut Simulations Plus from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Seven investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Simulations Plus presently has an average rating of “Reduce” and an average target price of $17.25.

Simulations Plus Stock Performance

The stock has a market capitalization of $373.45 million, a P/E ratio of 46.15 and a beta of 1.33. The firm’s fifty day simple moving average is $18.37 and its 200 day simple moving average is $16.26.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings results on Thursday, July 9th. The technology company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.07. The company had revenue of $21.89 million during the quarter, compared to the consensus estimate of $20.90 million. Simulations Plus had a net margin of 9.88% and a return on equity of 13.50%.

Insider Buying and Selling

In other Simulations Plus news, Director Walter Woltosz sold 4,177 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $18.44, for a total transaction of $77,023.88. Following the completion of the sale, the director directly owned 3,202,131 shares in the company, valued at $59,047,295.64. This represents a 0.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Simulations Plus

Several hedge funds and other institutional investors have recently modified their holdings of SLP. Integrated Wealth Concepts LLC acquired a new position in shares of Simulations Plus during the 2nd quarter worth $26,000. GAMMA Investing LLC grew its position in Simulations Plus by 26.0% in the second quarter. GAMMA Investing LLC now owns 2,831 shares of the technology company’s stock valued at $52,000 after acquiring an additional 585 shares during the last quarter. PNC Financial Services Group Inc. grew its position in Simulations Plus by 59.3% in the first quarter. PNC Financial Services Group Inc. now owns 4,485 shares of the technology company’s stock valued at $53,000 after acquiring an additional 1,669 shares during the last quarter. Fifth Third Bancorp acquired a new position in Simulations Plus during the first quarter worth about $54,000. Finally, Caitong International Asset Management Co. Ltd raised its stake in Simulations Plus by 343.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,983 shares of the technology company’s stock worth $73,000 after acquiring an additional 3,084 shares in the last quarter. Institutional investors own 78.08% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops software and provides consulting services for pharmaceutical and biotechnology companies involved in drug discovery and development. Its modeling and simulation tools are designed to help researchers evaluate drug candidates, understand how medicines move through the body, assess safety risks and support decisions throughout the development process.

The company’s products include GastroPlus, a platform used for physiologically based pharmacokinetic and biopharmaceutic modeling; ADMET Predictor, which helps predict absorption, distribution, metabolism, excretion and toxicity characteristics; and DILIsym, a software platform focused on drug-induced liver injury.